Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.79 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.67 |
| ▸ | MPC2 | O95563 | 1/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213719 | 0.93 | PPARG (0.80) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6928264 | 0.90 | PPARG (0.75) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6931380 | 0.90 | PPARG (0.75) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6929632 | 0.90 | PPARG (0.75) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL19217858 | 0.89 | PPARG (0.73) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL19217587 | 0.89 | PPARG (0.76) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL935983 | 0.88 | PPARG (1.00) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL12517394 | 0.88 | PPARG (0.81) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6928620 | 0.88 | PPARG (1.00) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6931666 | 0.88 | PPARG (0.81) | PPARGFFAR1MPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2512470-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OCTETA THERAPEUTICS LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2011084456-A9 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011084453-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084459-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084456-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011075514-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |